Komori
OncoTherapy Science (4564) · RiskRestated

Risk of large-scale purchases that could impair corporate value and the common interests of shareholders

First written in FY2016. 10 of 11 entries say "Restated". Latest entry: FY2020-Q3.

11entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2020-Q32016: 320162017: 320172018: 220182019: 220192020: 1
Same theme, other companies
Large-Scale Share Purchases and Acquisition Proposals that May Damage Enterprise ValueA theme 119 companies write about · 120 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2025: 3 of 26 companies on the "Worse" side.

86 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 119 companies compared. The sentences above are computed from all 119.
Full recordFilings, disclosures and news, newest first
  1. FY2020-Q3RestatedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, while others cannot be said to adequately reflect the Group's corporate value. Nor can it be ruled out that a large-scale purchase could be carried out without sufficient information being provided for shareholders to make a final decision.」

    The company continues to express concern about large-scale purchases that could impair corporate value and the common interests of shareholders.
  2. FY2020-Q2RestatedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, or」

    The company continues to express concern about large-scale purchases that could impair corporate value and the common interests of shareholders.
  3. FY2020-Q1RestatedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, while others cannot be said to adequately reflect the Group's corporate value. Nor can it be ruled out that a large-scale purchase could be carried out without sufficient information being provided for shareholders to make a final decision.」

    The company continues to express concern about large-scale purchases that could impair corporate value and the common interests of shareholders.
  4. FY2018RestatedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, or」

    The company continues to express concern about large-scale purchases that could impair corporate value and the common interests of shareholders.
  5. FY2018-Q3RestatedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, while others cannot be said to adequately reflect the Group's corporate value. Nor can it be ruled out that a large-scale purchase could be carried out without sufficient information being provided for shareholders to make a final decision.」

    The company continues to describe its concerns about large-scale purchases that could impair corporate value and the common interests of shareholders.
  6. FY2018-Q2RestatedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, while others cannot be said to adequately reflect the Group's corporate value. Nor can it be ruled out that a large-scale purchase could be carried out without sufficient information being provided for shareholders to make a final decision.」

    The company continues to describe its concerns about large-scale purchases that could impair corporate value and the common interests of shareholders.
  7. FY2017RestatedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, while others cannot be said to adequately reflect the Group's corporate value. Nor can it be ruled out that a large-scale purchase could be carried out without sufficient information being provided for shareholders to make a final decision.」

    The company continues to describe its concerns about large-scale purchases that could impair corporate value and the common interests of shareholders.
  8. FY2017-Q3RestatedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, while others cannot be said to adequately reflect the Group's corporate value. Nor can it be ruled out that a large-scale purchase could be carried out without sufficient information being provided for shareholders to make a final decision.」

    The company continues to describe its concerns about large-scale purchases that could impair corporate value and the common interests of shareholders.
  9. FY2017-Q2RestatedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, while others cannot be said to adequately reflect the Group's corporate value. Nor can it be ruled out that a large-scale purchase could be carried out without sufficient information being provided for shareholders to make a final decision.」

    The company continues to recognize the risks associated with large-scale purchases underlying the takeover defense measures.
  10. FY2017-Q1RestatedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, while others cannot be said to adequately reflect the Group's corporate value. Nor can it be ruled out that a large-scale purchase could be carried out without sufficient information being provided for shareholders to make a final decision.」

    The company continues to describe its recognition of the risks associated with large-scale purchases underlying the takeover defense measures.
  11. FY2016First statedAnnual report

    「Some large-scale purchase proposals could impair the Group's corporate value and the common interests of shareholders, for example, where it is expected to be difficult to maintain good relationships with stakeholders, while others cannot be said to adequately reflect the Group's corporate value.」

    The company disclosed this as the background to the takeover defense measures envisaging purchases of 20% or more.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of large-scale purchases that could impair corporate value and the common interests of shareholders | OncoTherapy Science,Inc. (4564) | Komori